1. Home
  2. AHG vs DBVT Comparison

AHG vs DBVT Comparison

Compare AHG & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHG

Akso Health Group ADS

BUY

Current Price

$1.41

Market Cap

976.6M

ML Signal

BUY

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

HOLD

Current Price

$8.90

Market Cap

850.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHG
DBVT
Founded
2013
2002
Country
China
France
Employees
N/A
90
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
976.6M
850.9M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
AHG
DBVT
Price
$1.41
$8.90
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $38.55
AVG Volume (30 Days)
103.0K
★ 338.0K
Earning Date
07-23-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 10.26
EPS
★ N/A
N/A
Revenue
N/A
★ $5,636,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,630.16
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 35.77
52 Week Low
$0.68
$8.86
52 Week High
$2.50
$26.19

Technical Indicators

Market Signals
Indicator
AHG
DBVT
Relative Strength Index (RSI) 72.12 27.45
Support Level $1.35 N/A
Resistance Level $1.57 $14.90
Average True Range (ATR) 0.14 0.46
MACD 0.05 -0.11
Stochastic Oscillator 88.99 7.44

Price Performance

Historical Comparison
AHG
DBVT

About AHG Akso Health Group ADS

Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: